Entrada Therapeutics, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Entrada Therapeutics, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Entrada Therapeutics, Inc. do? Business model and key facts
Get the full picture of Entrada Therapeutics, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 183
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Stocks related to Entrada Therapeutics, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Entrada Therapeutics, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Entrada Therapeutics, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
